Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

DSpace Repository

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Author: Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Mcdermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Rini, Brian I.
Tübinger Autor(en):
Bedke, Jens
Published in: European Urology (2023), Bd. 84, H. 5, S. 449-454
Verlagsangabe: Amsterdam : Elsevier
Language: English
Full text: http://dx.doi.org/10.1016/j.eururo.2023.06.006
ISSN: 0302-2838
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)